Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis.

Cerebrospinal fluid (CSF) cryptococcal colony-forming unit counts and CSF cryptococcal antigen titers serve as alternative measures of organism load in cryptococcal meningitis. For these measures, we correlated baseline values and rates of decline during the first 2 weeks of therapy in 68 human immunodeficiency virus--seropositive patients with cryptococcal meningitis. At baseline, there was a strong correlation between CSF cryptococcal colony-forming unit counts and CSF cryptococcal antigen titers. During the first 2 weeks of therapy, CSF cryptococcal colony-forming unit counts decreased by >5 logs, and CSF cryptococcal antigen titers decreased by 1.5 dilutions. In individual patients, there was no correlation between the rate of decline in CSF cryptococcal colony-forming unit counts and that in CSF cryptococcal antigen titers.

[1]  Indrani Bose,et al.  A Yeast under Cover: the Capsule of Cryptococcus neoformans , 2003, Eukaryotic Cell.

[2]  R. Hayes,et al.  Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  L. Weinhold,et al.  In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. , 2001, The Journal of infectious diseases.

[4]  J. Whitworth,et al.  Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. , 1998, International journal of epidemiology.

[5]  M. Saag,et al.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. , 1997, The New England journal of medicine.

[6]  A. Casadevall,et al.  Polysaccharide antigen in brain tissue of AIDS patients with cryptococcal meningitis. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Saag,et al.  Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  M. Saag,et al.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. , 1992, The New England journal of medicine.

[9]  S. Chuck,et al.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[10]  R. Diasio,et al.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. , 1987, The New England journal of medicine.

[11]  R. Eng,et al.  Cryptococcal infections in patients with acquired immune deficiency syndrome. , 1986, The American journal of medicine.

[12]  D. Alling,et al.  A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. , 1979, The New England journal of medicine.

[13]  J. Bennett,et al.  Prognostic factors in cryptococcal meningitis. A study in 111 cases. , 1974, Annals of internal medicine.

[14]  R. Larsen,et al.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.